Menopausal Hormone Therapy and Risk for Cardiovascular Disease in the WHI Trial
Authors: Amos Pines
Journal: Annals of Internal Medicine (2010)

Letters6 July 2010Menopausal Hormone Therapy and Risk for Cardiovascular Disease in the WHI TrialAmos Pines, MD and David Sturdee, MBBS, MD, DAAmos Pines, MDFrom The International Menopause Society, LA2 8WY Lancaster, United Kingdom.Search for more papers by this author and David Sturdee, MBBS, MD, DAFrom The International Menopause Society, LA2 8WY Lancaster, United Kingdom.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-153-1-201007060-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Since the first article from the WHI in 2002, the validity of the methods of data analysis has been debated. First, debate focused on the use of adjusted or unadjusted hazard ratios, then on the issue of combining the data from the group that received conjugated equine estrogen with medroxyprogesterone acetate and the group that received conjugated equine estrogen alone, or the data from the WHI clinical study and the WHI observational study. Recently, when age became an important variable in the risk–benefit balance of hormone therapy, another debate involved the “timing hypothesis.” Although these arguments are ...References1. Toh S, Hernández-Díaz S, Logan R, Rossouw JE, Hernán MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med. 2010;152:211-7. [PMID: 20157135] LinkGoogle Scholar2. Summaries for patients: the effect of estrogen plus progestin on coronary heart disease. Ann Intern Med. 2010;152:I-40. [PMID: 20157120] MedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Amos Pines, MD; David Sturdee, MBBS, MD, DAAffiliations: From The International Menopause Society, LA2 8WY Lancaster, United Kingdom.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCoronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Disappear? Sengwee Toh , Sonia Hernández-Díaz , Roger Logan , Jacques E. Rossouw , and Miguel A. Hernán The Effect of Estrogen Plus Progestin on Coronary Heart DiseaseMenopausal Hormone Therapy and Risk for Cardiovascular Disease in the WHI Trial Jerome L. Sullivan Menopausal Hormone Therapy and Risk for Cardiovascular Disease in the WHI Trial Sengwee Toh , Jacques E. Rossouw , and Miguel A. Hernán Menopausal Hormone Therapy and Risk for Cardiovascular Disease in the WHI Trial S. Mitchell Harman , Eliot A. Brinton , Frederick Naftolin , George R. Merriam , Marcelle I. Cedars , Ruth G. Freeman , and Nanette Santoro Metrics 6 July 2010Volume 153, Issue 1Page: 61KeywordsConflicts of interestCongenital heart diseaseEpidemiological statisticsEstrogensHazard ratioHormonal therapyHormonesMenopauseMyocardial infarctionObservational studies ePublished: 6 July 2010 Issue Published: 6 July 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...